Drug Safety Newsletter 65th Edition

Download: hpra-dsn-65th-edition.pdf 389 KB

The latest issue of the HPRA Drug Safety Newsletter (DSN) includes important updates to support safe and appropriate use of the following medicines:

  • Valproate-containing medicines: Recommendation to further restrict use in women and girls
  • Ivabradine (Procorlan): New contraindication and recommendations to minimise the risk of cardiovascular adverse events
  • Agomelatine (Valdoxan): Reminder of the importance of hepatic monitoring to reduce the risk of serious hepatic adverse reactions
  • Testosterone: EU review does not confirm increased risk of cardiovascular events

« Back